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Abstract
Introduction: Interstitial lung disease (ILD) is a common extra-articular condition in rheumatoid arthritis (RA), but
few studies have systematically investigated its incidence and risk factors in patients receiving anti-tumor necrosis
factor-alpha (anti-TNFα) agents or alternate mechanisms of action (MOAs) (e.g., T-cell, B-cell, and interleukin-6
inhibitors).
Methods: RA patients at least 18 years old were selected from the MarketScan databases (2010–2012) if they had
at least one prescription/administration of abatacept, rituximab, tocilizumab, or anti-TNF after having discontinued
a different biologic agent and meeting enrollment criteria. Cox models estimated the risk of incident ILD and
ILD-related hospitalization. Sensitivity analyses used an alternate ILD case definition.
Results: We identified 13,795 episodes of biologic exposure in 11,219 patients. Mean (standard deviation) follow-up
was 0.7 (0.5) years. Patients receiving alternate MOA agents were more likely to have had recent exposure to
steroids, prior exposure to a greater number of biologics, and history of ILD, anemia, chronic obstructive pulmonary
disease, and other pulmonary conditions. When the sensitive definition was used, unadjusted ILD incidence rates
(95 % confidence interval, or CI) ranged from 4.0 (1.6–8.2, abatacept) to 12.2 (5.6–23.2, infliximab) per 1000 person-years.
Being older (hazard ratio (HR) 3.5; 95 % CI 2.1–6.0), being male (HR 3.1; 95 % CI 1.2–8.4), and having another pulmonary
condition (HR 4.8; 95 % CI 1.7–13.7) were associated with increased ILD incidence in either sensitive and/or specific
models. There were no significant differences by biologic class. Hospitalization rates (95 % CI) when the sensitive
definition was used ranged from 55.6 (6.7–200.7, tocilizumab) to 262.5 (71.5–672.2, infliximab). In Cox models, recent
methotrexate exposure was associated with reduced ILD hospitalization (HR 0.16; 95 % CI 0.06–0.46), whereas being
male (HR 2.5; 95 % CI 1.3–4.8) and having had a hospitalization for asthma (HR 3.4; 95 % CI 1.2–9.8) or ILD/
pneumonia (HR 2.3; 95 % CI 1.1–4.7) in the 12 months prior to index were associated with increased
hospitalization risk.
Conclusions: There were no significant differences in the risk of ILD and its related complications between RA
patients receiving anti-TNFα agents and those receiving alternate MOA agents. Further studies are needed that
account for differences in baseline characteristics in order to fully evaluate the risk of ILD and its complications.
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Introduction
Roughly half of patients with rheumatoid arthritis (RA)
will have some form of extra-articular involvement, such
as interstitial lung disease (ILD) [1–3]. ILD refers to a
collection of lung disorders classified together because
they all affect the tissue and space around the alveoli
called the interstitium. Depending on the specific disease
in question, the alveoli, airways, blood vessels, and
pleura may also be affected. Manifestations of ILD
include respiratory symptoms (e.g., dyspnea and non-
productive cough), specific chest radiographic abnormal-
ities, decreased lung volume, and microscopic patterns
of inflammation and fibrosis [4]. Although the condition
is heterogeneous in RA, the majority of cases are similar
to non-specific interstitial pneumonia and usual intersti-
tial pneumonia. The prevalence of ILD in patients with
RA varies from 5 % to 58 %, depending on the ILD case
definition and RA severity in the population studied [5–7].
The 1-year incidence of ILD has been reported at 2.8 % [8].
Symptoms may be subtle or non-existent at onset, despite
patients having radiographic features consistent with ILD.
Cigarette smoking and high levels of circulating
rheumatoid factor and anti-cyclic citrullinated peptides
have been identified as risk factors for ILD. Drug-
induced ILD has been reported in the past as a rare but
severe adverse event associated with a number of agents
used to treat RA, namely non-steroidal anti-inflammatory
drugs, intravenous immunoglobulin, gold, methotrexate,
leflunomide, and cyclophosphamide [9–13]. New-onset
ILD or ILD worsening has also been reported as a possible
consequence of biologic agents, including three of the
most widely used anti-tumor necrosis factor alpha
(anti-TNFα) inhibitors (infliximab, etanercept, and ada-
limumab) [12–16]. However, these associations are fre-
quently based on case reports, in differing patient
populations with multiple medication exposures and
using various definitions of ILD.
It has been hypothesized that biologic therapy might
cause serious respiratory events by inducing idiosyn-
cratic reactions, accelerating pre-existing ILD, modifying
ILD into a more injurious phenotype, or increasing sus-
ceptibility to infection, yet the precise mechanism of ac-
tion (MOA) is unknown [17, 18]. These agents may also
have a therapeutic effect in RA-ILD since inflammatory
cytokines, including TNF, are elevated in patients with
idiopathic pulmonary fibrosis. Studies have been con-
ducted to assess the benefit of these agents as therapy
for ILD. One study demonstrated a non-statistically sig-
nificant reduction in ILD progression, and a second trial
is still under way [17].
The present study evaluated ILD incidence and exacer-
bation among users of abatacept (T-cell inhibitor), ritux-
imab (B-cell inhibitor), and tocilizumab (interleukin-6
(IL-6) inhibitor) compared with anti-TNFα agents in a
cohort of adult RA patients who previously had expos-
ure to at least one biologic therapy.
Methods
Data source
The data source for this retrospective cohort study was
the MarketScan Commercial Claims and Encounters
(Commercial) and the Medicare Supplemental and
Coordination of Benefit (Medicare) databases. Both data-
bases contain de-identified health insurance enrollment
information and claims data for inpatient and outpatient
medical services as well as outpatient prescriptions. The
commercial database includes employees, spouses, and
dependents covered by employer-sponsored private
health insurance. The Medicare database profiles the
health-care experience of retirees with Medicare supple-
mental insurance paid by employers. All patient data
used in this analysis were de-identified in compliance
with the Health Insurance Portability and Accountability
Act and as such did not require institutional review
board approval.
Patient population
RA patients, at least 18 years old, were selected into the
study provided that they had a prescription or adminis-
tration of a new biologic agent between 1 January 2010
and 30 June 2012, evidence of having previously discon-
tinued a different biologic agent at any time in the past,
and at least one diagnosis of RA (ICD-9-CM 714.0,
714.3) on a non-diagnostic claim either during the base-
line period or within the first 30 days of follow-up. Prior
biologic use was required in order to homogenize the
patient population to those individuals with more refrac-
tory disease who had received biologics in the past and
to allow better comparability with patients using second-
and third-line agents. The study index date was the date
of first prescription/administration of the biologic agent
for which the patient met all eligibility requirements.
Patients were required to be continuously enrolled for at
least 12 months prior to index and to have had both
medical and pharmacy benefit plus complete data avail-
ability during both baseline and follow-up periods. Patients
with a history of malignancy (ICD-9-CM 140–171, 174–
209, 230–234), ulcerative colitis (ICD-9-CM 556.xx),
psoriatic arthritis (ICD-9-CM 696.0x), Crohn disease
(ICD-9-CM 555.xx), psoriasis (ICD-9-CM 696.1x),
or ankylosing spondylitis (ICD-9-CM 720.xx) during
the 12 months prior to index were excluded from
the study. Patients with baseline evidence of prior use
of the qualifying biologic were also deemed study-
ineligible.
Each patient was permitted to contribute multiple epi-
sodes to the analytic data set. Patients were followed
within each treatment episode until disenrollment from
Curtis et al. Arthritis Research & Therapy  (2015) 17:319 Page 2 of 13
MarketScan, end of the study period, discontinuation of
the qualifying biologic, addition of a new biologic agent,
onset of any malignancy, or the primary study outcome,
incident ILD. A second endpoint, the occurrence of an
ILD complication, was examined in a separate analysis
in a cohort of RA patients with a history of ILD.
Cohort definitions
Treatment episodes were constructed for each individual
biologic agent by computing drug exposure on each day
of the study. Pharmacy-based exposure was based on the
date of fill and number of days of supply associated with
each prescription. For provider-administered injectable
or infused medications, exposure was based on the
administration date and a clinically relevant exposure
window. Administrations of etanercept were assigned a
7-day coverage window, whereas adalimumab and certo-
lizumab were assigned a 14-day coverage window.
Administration of tocilizumab and abatacept was
assigned a 28-day coverage window, rituximab 183 days,
infliximab 56 days, and injectable corticosteroids a 28-
day coverage window. To capture events that might have
occurred shortly after discontinuation while an agent’s
effects were still material and to address changes in
medication instruction that may have occurred after the
issuance of the original prescription, a fixed grace period
of 90 days was applied to all claims, pharmacy-issued or
physician/facility-administered. Sensitivity analyses that
expanded the grace period from 90 to 120 days were
conducted.
Health-care providers obtain reimbursement for medi-
cations by using Healthcare Common Procedure Coding
System (HCPCS) codes. Claims for newly licensed medi-
cations use a non-specific HCPCS code (e.g., J3490 and
J3590) until a unique HCPCS code specific to each drug
is assigned, usually 1–2 years post-launch. We adapted a
validated algorithm [19] in order to identify both toci-
lizumab and certolizumab pegol claims from the pool of
unclassified drugs/biologics claims. This algorithm, de-
veloped by using Medicare data linked to an arthritis
registry, had good performance characteristics: sensitiv-
ity of 94 % (95 % confidence interval (CI) 80 %–99 %),
specificity of 100 % (95 % CI 99 %–100 %), and positive
predictive value of 97 % (95 % CI 84 %–100 %) [20].
Treatment episodes were constructed at the level of
each biologic agent, but for reporting purposes, exposure
was collapsed into one of four groups: tocilizumab, aba-
tacept, rituximab, and all anti-TNFα agents in aggregate.
Only ILD incidence and complication rates were
presented separately by individual anti-TNF agent.
Study outcomes
The primary study outcome was the incidence of ILD.
Given the well-documented challenges in ILD case
ascertainment, especially in claims-based data, we de-
fined ILD both conservatively, using a more specific
definition, as well as more broadly, in order to
maximize sensitivity [21]. The two definitions differed
in the ICD-9-CM diagnosis (Appendix), the position of
the ILD diagnosis on the claim, and the presence of an
eligible ILD diagnostic test (computed tomography
(CT) scan of the thorax or lung biopsy) within 90 days
of the ILD diagnosis. Definition 1, the more specific
definition, included diagnoses of post-inflammatory
pulmonary fibrosis and idiopathic interstitial pneumo-
nia, required that diagnoses on inpatient claims be in
the primary position, and required that the ILD diag-
nostic test occur in the 90 days prior to diagnosis. In
contrast, definition 2, the more sensitive definition,
included diagnoses of rheumatoid lung and other speci-
fied and unspecified alveolar and parietoalveolar pneu-
monopathies, accepted these diagnoses in any claim
position, and did not require evidence of a preceding
ILD diagnostic test.
The second study outcome was the frequency of hos-
pitalizations for ILD or an ILD-related complication in
patients with a baseline history of ILD. Eligible hospitali-
zations included hospitalization with a primary diagnosis
of ILD, pneumonia (ICD-9-CM 480.xx-486.xx, 487.0x),
or lung transplant. Hospitalization was chosen as a
proxy of ILD-related exacerbations or complications.
Only the first event was measured and evaluated since
the duration of ILD exacerbation varies.
Statistical analysis
Descriptive results were produced twice: once with the
more specific definition of ILD and a second time with
the more sensitive definition. Basic analyses included
descriptive profiles of all independent and dependent vari-
ables. Categorical variables were summarized in frequency
tables. Continuous and other numerical variables were
summarized by the number of observations, means, stand-
ard deviations (SDs), and medians. Statistical tests of sig-
nificance for differences in these distributions were
carried out with chi-squared tests used to assess the statis-
tical significance of categorical variables; t tests and ana-
lysis of variance were used for continuous variables.
Generalized estimating equations were used to adjust for
clustering.
The number and proportion of patients with each
event (incident ILD and ILD-related hospitalization), as
well as the rate per 1000 person-years (PY) of observa-
tion, were reported. Cox proportional hazards models
were developed to assess the relative hazard of each
event during follow-up, adjusting for differences in base-
line characteristics among the biologic exposure groups.
The relative hazard of ILD incidence was estimated as a
function of age group (<65 years reference), study cohort
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(anti-TNF cohort reference), gender (female reference),
recent glucocorticoid or methotrexate exposure defined
as exposure in the 6 months prior to index, or baseline
history of a pulmonary condition—chronic obstructive
pulmonary disease (COPD), asthma, or pneumonia—-
other than ILD. In the assessment of ILD complications
among patients with a history of ILD, only one Cox pro-
portional hazards model could be constructed because
of small event counts, estimated as a function of age
group (<65 years reference), study cohort (anti-TNF
cohort reference), gender (female reference), recent
glucocorticoid or methotrexate exposure defined as ex-
posure in the 6 months prior to index, or a recent
hospitalization with a diagnosis of asthma, COPD, ILD,
or pneumonia. The latter variables were used as proxies
for the severity or complexity of ILD.
Results
There were 114,010 patients in the MarketScan data
extract, with 1.2 million claims for a biologic medica-
tion during the case selection window (1 January 2010
through 30 June 2012). Sixty percent of these patients
(n = 67,874) were classified as “new” users since they
had no evidence of prior exposure to the qualifying bio-
logic using all available claims data (2001–2012) during
the period prior to their 79,525 potentially eligible epi-
sodes. Fewer than half of these patients (44.6 %; n =
30,267) met age-eligible (at least 18 years) and benefit-
eligible continuous enrollment criteria (at least
12 months prior to index), and only half of patients
meeting enrollment and age criteria had evidence of
prior use of any other biologic (49 %; n = 14,681). An
additional 23 % of patients in total were deemed ineli-
gible because of other criteria (no RA diagnosis, clinical
history of psoriatic arthritis, ankylosing spondylitis,
cancer, inflammatory bowel disease, or psoriasis). Once
the eligible study population was identified, patients
were segmented into those with (499 episodes and 419
patients) and without (13,296 episodes and 10,800 pa-
tients) a history of ILD. Those patients who did not
have a history of prevalent ILD were eligible for the
ILD incidence study, whereas those with a history were
eligible for the complications portion of the study.
Figure 1 depicts accrual graphically.
Patient characteristics
Patients without a history of ILD
Despite differences in the ILD detection rate associated
with each ILD definition, there was little variability in
patient characteristics. These characteristics, presented
in tabular form in Table 1 and summarized below, were
based on the most sensitive ILD definition. Patients were
exposed on average for 0.7 years (8.3 months), with little
variation across the biologic exposure group.
There was considerable variability in prior exposure to
RA medications across cohorts. Mean (SD) number of




No Prior Use of The 
Qualifying Biologic
N = 67,874 59.5%
> 12 months Continuous 
Enrollment and 18 years of Age
N = 30,267 44.6%
Evidence of Prior Use of
Another Biologic and RA
Diagnosis
N = 13,130 43.4%
No Hx of IBD, Malignancy,
PA, AS or Psoriasis
N = 11,219 85.4%
No Hx of ILD
Definition 1, Most Specific
Patients = 11,140
Episodes = 13,698
No Hx of ILD
Definition 2, Most Sensitive
Patients = 10,816
Episodes = 13,296
Hx of IBD, Malignancy,
PA, AS or Psoriasis
N = 1,911 14.6%
No Evidence of Prior Use
of Another Biologic or No 
RA Diagnosis
N = 17,137 56.6%
< 12 months Continuous 
Enrollment or <18 years of Age
N = 37,607 55.4%
Prior Use of The 
Qualifying Biologic
N = 46,136 40.5%
<
Fig. 1 Application of selection criteria and patient disposition. AS ankylosing spondylitis, Hx history, IBD inflammatory bowel disease, ILD interstitial
lung disease, PA psoriatic arthritis, RA rheumatoid arthritis
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N = 7951 N = 1528 N = 1134 N = 2683
Female, n (%)a 6462 (81.3) 1267 (82.9) 931 (82.1) 2228 (83.0)
Age, mean (SD)a 51.7 (12.5) 53.8 (12.0) 53.8 (12.1) 53.9 (12.6)
Geographic region, n (%)a
Northeast 1285 (16.2) 230 (15.1) 172 (15.2) 393 (14.6)
North Central 1866 (23.5) 382 (25.0) 306 (27.0) 686 (25.6)
South 3212 (40.4) 583 (38.2) 411 (36.2) 1100 (41.0)
West 1536 (19.3) 323 (21.1) 235 (20.7) 481 (17.9)
Rural indicator, n (%)a, b 1315 (16.5) 225 (14.7) 216 (19.0) 392 (14.6)
Medicare primary payer, n (%)a, b 1001 (12.6) 245 (16.0) 195 (17.2) 488 (18.2)
Follow-up person years per patient, mean (SD) 0.7 (0.6) 0.7 (0.5) 0.7 (0.5) 0.7 (0.5)
No of prior biologics, mean (SD)b, c 1.4 (0.7) 2.1 (1.1) 1.9 (0.9) 1.6 (0.8)
Prior exposure to ≥2 biologics 990 (12.5) 715 (46.8) 334 (29.5) 198 (7.4)
Prior exposure to ≥3 biologics 186 (2.3) 136 (8.9) 40 (3.5) 4 (0.1)
RA medication history, n (%)d
Any anti-TNFα agentb 5532 (69.6) 617(40.4) 571 (50.4) 1865 (69.5)
Methotrexate 4293 (54.0) 785 (51.4) 604 (53.3) 1361 (50.7)
All other DMARDs 2575 (32.4) 531 (34.8) 410 (36.2) 883 (32.9)
Prescription NSAIDs 3407 (42.8) 635 (41.6) 449 (39.6) 1080 (40.3)
Glucocorticoid daily dosage, mean (SD)e
Noneb 2307 (29.0) 299 (19.6) 214 (18.9) 599 (22.3)
<7.5 mg/day 4355 (54.8) 864 (56.5) 642 (56.6) 1534 (57.2)
≥7.5 mg/dayb 1285 (16.2) 362 (23.7) 278 (24.5) 549 (20.5)
Comorbid condition, n (%)f
Anemiab 163 (2.1) 45 (2.9) 29 (2.6) 52 (1.9)
Asthma 294 (3.7) 76 (5.0) 47 (4.1) 118 (4.4)
Cerebrovascular disease 131 (1.6) 20 (1.3) 21 (1.9) 44 (1.6)
COPDb 209 (2.6) 59 (3.9) 40 (3.5) 92 (3.4)
Diabetes 845 (10.6) 176 (11.5) 150 (13.2) 298 (11.1)
Heart failure 72 (0.9) 23 (1.5) 25 (2.2) 38 (1.4)
Hypertension 1776 (22.3) 372 (24.3) 297 (26.2) 663 (24.7)
Ischemic heart diseaseb 361 (4.5) 81 (5.3) 58 (5.1) 143 (5.3)
Pneumonia 148 (1.9) 34 (2.2) 35 (3.1) 74 (2.8)
Any pulmonary condition other than ILDb 600 (7.5) 162 (10.6) 112 (9.9) 246 (9.2)
Scleroderma 15 (0.2) 3 (0.2) 7 (0.6) 2 (0.1)
Sjögren’s 121 (1.5) 32 (2.1) 19 (1.7) 51 (1.9)
SLE 122 (1.5) 26 (1.7) 37 (3.3) 52 (1.9)
Deyo-adapted CCI, mean (SD)f 1.5 (1.0) 1.6 (1.1) 1.6 (1.2) 1.6 (1.0)
ILD interstitial lung disease, TNF tumor necrosis factor, SD standard deviation, RA rheumatoid arthritis, DMARD disease-modifying anti-rheumatic drug, NSAID
non-steroidal anti-inflammatory drug, COPD chronic pulmonary disease, SLE systemic lupus erythematosus, CCI Charlson comorbidity index
a Demographics measured at study index
bP < 0.05, tocilizumab versus all other cohorts combined
c Using available data
d In the 6 months prior to study index
e Prednisone equivalents
f In the 12 months prior to study index
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unique biologic agents received prior to index was sig-
nificantly (P < 0.0001) higher among tocilizumab users
(mean, 2.1; SD, 1.1) and lower among users of anti-TNF
agents (mean, 1.4; SD, 0.7). Half of tocilizumab users
had prior exposure to at least two biologics, and 25 %
had exposure to at least three agents. In contrast, half of
anti-TNF users had exposure to one prior biologic, and
25 % had exposure to at least two. Half (53.0 %) of pa-
tient episodes involved exposure to methotrexate in the
6 months prior to index, and 33 % were exposed to an-
other non-biologic disease-modifying anti-rheumatic
drug other than methotrexate; 42 % had recent exposure
to prescription non-steroidal anti-inflammatory drugs.
Recent exposure to glucocorticoids was highest among
rituximab (81.1 %) and tocilizumab (80.4 %) episodes
and lowest among anti-TNF agent (71.0 %) episodes
(P < 0.0001). Tocilizumab and rituximab episodes not
only were more likely to have had exposure to gluco-
corticoids but also were significantly (P < 0.0001) more
likely to receive higher mean daily dosages (at least
7.5 mg/day) than were anti-TNF or abatacept
episodes.
A little more than 8 % of the population had a history
of some other form of pulmonary disease, primarily
asthma (4.0 %), COPD (3.0 %), or pneumonia (2.2 %).
Tocilizumab, rituximab, and abatacept episodes were
more likely to have one of these pulmonary conditions
(10.6 %, 9.9 %, and 9.2 % versus 7.5 %; P < 0.05) in the
12 months prior to index compared with anti-TNF treat-
ments. Despite these differences, there was no statisti-
cally significant difference in the Deyo-adapted Charlson
comorbidity index across cohorts. Baseline evidence of
scleroderma, Sjögren’s, and systemic lupus erythemato-
sus (SLE) occurred in 0.2 %, 1.7 %, and 1.8 % of epi-
sodes, respectively. There were no significant differences
in the occurrence of these conditions across cohorts.
Patients with a baseline history of ILD
Table 2 depicts patient characteristics for patients with a
history of ILD. One fifth of all patients with a history of
ILD also had a history of oxygen use during baseline,
reflecting in part ILD history but also other pulmonary
disorders, which occurred in 38 % of episodes. Patients
with a history of ILD and exposure to tocilizumab or ri-
tuximab were more likely to have a baseline history of
pneumonia (25.4 % and 24.2 % versus 15.1 %) and
COPD (22.0 % and 27.3 % versus 17.7 %) compared with
patients exposed to anti-TNF therapy. Patients with a
history of ILD and exposure to rituximab were more
likely to have a recent (12 months prior to index)
hospitalization for ILD, pneumonia, asthma, or COPD.
It should also be noted that compared with patients
without an ILD history, patients with a history of ILD
were significantly more likely to receive rituximab
(19.8 % versus 8.5 %; P < 0.0001) and significantly less
likely to receive anti-TNF therapy (46.5 % versus 59.8 %;
P < 0.0001). Although the frequency of scleroderma,
Sjögren’s, and SLE was higher than was observed in the
population with ILD history, occurring in 2.6 %, 2.4 %,
and 2.4 % of episodes, respectively, there were no signifi-
cant differences across cohorts.
ILD incidence
Table 3 presents ILD incidence event counts and rates
(95 % CI) for both specific and sensitive definitions.
Overall, ILD incidence rate ranged from 1.8 per 1000 PY
using the most specific definition to 6.4 using the most
sensitive definition. Regardless of the definition
employed, the vast majority (75 %–83 %) of events had
at least one diagnosis code for post-inflammatory pul-
monary fibrosis (ICD-9 CM 515.xx). Unadjusted ILD in-
cidence (specific definition) rates, by cohort, ranged
from a low of zero in the etanercept and golimumab co-
horts to a high of 4.7 in the rituximab cohort. When the
most sensitive definition was used, unadjusted ILD inci-
dence rates ranged from a low of 4.0 in the abatacept co-
hort to a high of 12.2 (95 % CI 5.6–23.2) in the
infliximab cohort. There was no statistically significant
difference in the rate of ILD incidence, unadjusted,
across cohorts.
Cox model results using both ILD definitions are pre-
sented in Fig. 2. When the most sensitive ILD defin-
ition was used, membership in the cohort of patients at
least 65 years old was associated with increased risk of ILD
(hazard ratio (HR) 3.54; 95 % CI 2.07–6.03; P < 0.0001),
while recent exposure to glucocorticoids was associated
with marginally increased risk (HR 1.99; 95 % CI 0.98–4.06;
P = 0.0586). Cox model results using the most specific ILD
definition suggested increased incidence associated with
being male (HR 3.09; 95 % CI 1.14–8.35; P = 0.0258) and
having a baseline history of other pulmonary conditions
(HR 4.83; 95 % CI 1.71–13.68; P = 0.0030). No other vari-
ables were significant in this model. The relative hazard,
compared with anti-TNF agents, associated with exposure
to abatacept, rituximab, or tocilizumab was not significantly
increased.
ILD hospitalization
Table 4 presents ILD-related hospitalization event
counts and rates (95 % CI) for both specific and sensitive
definitions. ILD-related hospitalization rates ranged from
65.8 per 1000 PY to 127.7 using the specific and sensitive
definitions, respectively. When either definition was used,
the primary diagnosis for hospitalization was split evenly
between ILD and pneumonia, with a single patient having
a lung transplant. ILD-related hospitalization rates using
the most specific definition ranged from a low of zero in
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N = 232 N = 59 N = 99 N = 109
Female, n (%)a 172 (74.1) 47 (79.7) 75 (75.8) 82 (75.2)
Age, mean (SD)a 60.4 (11.9) 59.4 (12.3) 62.1 (11.0) 61.2 (10.3)
Geographic region, n (%)a
Northeast 36 (15.5) 9 (15.3) 13 (13.1) 15 (13.8)
North Central 73 (31.5) 16 (27.1) 42 (42.4) 35 (32.1)
South 78 (33.6) 26 (44.1) 24 (24.2) 43 (39.4)
West 43 (18.5) 8 (13.6) 20 (20.2) 15 (13.8)
Rural indicator, n (%)a 32 (13.8) 6 (10.2) 18 (18.2) 20 (18.3)
Medicare primary payer, n (%)a 78 (33.6) 17 (28.8) 43 (43.4) 35 (32.1)
Follow-up person years per patient, mean (SD) 0.7 (0.5) 0.6 (0.5) 0.7 (0.5) 0.7 (0.6)
No of prior biologics, mean (SD)b,c 1.6 (0.9) 2.3 (1.2) 1.7 (0.9) 1.6 (0.9)
Prior exposure to ≥2 biologics 45 (19.4) 30 (50.8) 27 (27.3) 10 (9.2)
Prior exposure to ≥3 biologics 12 (5.2) 6 (10.2) 2 (2.0 0 (0.0)
RA medication history, n (%)d
Any anti-TNFα agentb 135 (58.2) 21 (35.6) 42 (42.4) 69 (63.3)
Methotrexate 73 (31.5) 25 (42.4) 39 (39.4) 44 (40.4)
All other DMARDs 108 (46.6) 21 (35.6) 52 (52.5) 54 (49.5)
Prescription NSAIDs 98 (42.2) 22 (37.3) 31 (31.3) 37 (33.9)
Glucocorticoid daily dosage, mean (SD)e
Noneb 40 (17.2) 7 (11.9) 9 (9.1) 21 (19.3)
<7.5 mg/day 124 (53.4) 28 (47.5) 44 (44.4) 57 (52.3)
≥7.5 mg/day 68 (29.3) 24 (40.7) 46 (46.5) 31 (28.4)
Comorbid condition, n (%)f
Anemiab 4 (1.7) 3 (5.1) 3 (3.0) 3 (2.8)
Asthma 23 (9.9) 5 (8.5) 12 (12.1) 5 (4.6)
Cerebrovascular disease 7 (3.0) 2 (3.4) 4 (4.0) 4 (3.7)
COPDb 41 (17.7) 13 (22.0) 27 (27.3) 18 (16.5)
Diabetes 41 (17.7) 16 (27.1) 20 (20.2) 25 (22.9)
Heart failure 12 (5.2) 5 (8.5) 8 (8.1) 12 (11.0)
Hypertension 72 (31.0) 20 (33.9) 34 (34.3) 36 (33.0)
Ischemic heart diseaseb 23 (9.9) 2 (3.4) 10 (10.1) 21 (19.3)
Pneumonia 35 (15.1) 15 (25.4) 24 (24.2) 17 (15.6)
Any pulmonary condition other than ILDb 81 (34.9) 26 (44.1) 50 (50.5) 32 (29.4)
Scleroderma 3 (1.3) 0 (0.0) 4 (4.0) 6 (5.5)
Sjögren’s 5 (2.2) 2 (3.4) 4 (4.0) 1 (0.9)
SLE 4 (1.7) 2 (3.4) 3 (3.0) 3 (2.8)
Any oxygen use, n (%)f 39 (16.8) 11 (18.6) 26 (26.3) 18 (16.5)
Hospitalization, n (%)g
ILD 18 (7.8) 9 (15.3) 21 (21.2) 13 (11.9)
Pneumonia 24 (10.3) 8 (13.6) 18 (18.2) 12 (11.0)
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each of the anti-TNF cohorts except etanercept to a high
of 261.5 in the etanercept cohort. CIs using the specific
definition are wide as would be expected, given the small
number of events (n = 4). Unadjusted hospitalization rates
using the most sensitive ILD definition ranged from a low
of 55.6 in the tocilizumab cohort to a high of 262.5 in the
infliximab cohort. There were no statistically significant
differences in ILD-related hospitalization rates, un-
adjusted, across the study cohorts.
Event counts were sufficient to support only a single
Cox model assessing the relative hazard of an ILD-related
hospitalization using the most sensitive definition. HRs
and CIs are presented in Fig. 3. Recent exposure to
methotrexate (HR 0.16; 95 % CI 0.06–0.46; P = 0.0007)
was associated with a significant reduction in the risk
of ILD-related hospitalizations, whereas being male
(HR 2.47; 95 % CI 1.28–4.78; P = 0.0073) or having
been hospitalized for asthma (HR 3.42; 95 % CI 1.19–
9.82; P = 0.0224) or ILD/pneumonia (HR 2.28; 95 % CI
1.11–4.67; P = 0.0245) in the 12 months prior to index
was significantly associated with an increased risk.
Discussion
Few studies have examined the risk of incident ILD
among patients exposed to anti-TNFs, abatacept, rituxi-
mab, and tocilizumab, and even fewer studies have
evaluated the risk of hospitalization in patients with pre-
existing ILD who are subsequently exposed to these
agents. Our study evaluated both outcomes in a large
cohort of RA patients exposed to biologic therapies and
found no significant difference in the risk of ILD inci-
dence between patients exposed to tocilizumab, rituxi-
mab, or abatacept compared with anti-TNFα therapies.
In addition, no differences in the risk of ILD complica-
tions between patient cohorts exposed to each of the
biologic agents were observed. Study findings confirmed
that, in a real-world setting, there were significant base-
line differences in patients exposed to alternate MOA as
compared with patients exposed to anti-TNFs. Patients
likely cycle between anti-TNFs before being given the
therapeutic option of tocilizumab, rituximab, or abata-
cept. As a result, patients exposed to alternate MOA
may have greater disease severity and duration. Physician
perceptions may also play a role in channeling patients
to and away from these newer therapies. Using data
Table 2 Baseline demographics and clinical characteristics: patients with ILD history using the most sensitive ILD definition
(Continued)
Asthma 5 (2.2) 1 (1.7) 5 (5.1) 1 (0.9)
COPD 20 (8.6) 1 (1.7) 14 (14.1) 7 (6.4)
Deyo-adapted CCI, mean (SD)f 2.2 (1.4) 2.1 (1.0) 2.4 (1.4) 2.4 (1.6)
ILD interstitial lung disease, TNF tumor necrosis factor, SD standard deviation, RA rheumatoid arthritis, DMARD disease-modifying anti-rheumatic drug, NSAID
non-steroidal anti-inflammatory drug, COPD chronic pulmonary disease, SLE systemic lupus erythematosus, CCI Charlson comorbidity index
a Demographics measured at study index
bP < 0.05, tocilizumab versus all other cohorts combined
c Using available data
d In the 6 months prior to study index
e Prednisone equivalents
f In the 12 months prior to study index
g Based on the presence of a diagnosis code for the condition in any position on the claim. Hospitalization could occur at any point during the 12 months prior to
study index, before, during or after diagnosis with ILD
Table 3 ILD incidence rate per 1000 PY, unadjusted
Cohort Specific definition Sensitive definition
Events (total PY) Events (total PY)
Rate (95 % CI) Rate (95 % CI)
All eligible 16 (9107) 59 (9154)
1.8 (1.0–2.9) 6.4 (4.9–8.3)
Anti-TNFα agents 9 (5473) 39 (5527)
1.6 (0.8–3.1) 7.1 (5.0–9.6)
Etanercept 0 (1012) 6 (1015)
0.0 (0.0–3.0) 5.9 (2.2-12.9)
Adalimumab 3 (1674) 12 (1692)
1.8 (0.4-5.2) 7.1 (3.7–12.4)
Infliximab 3 (735) 9 (738)
4.1 (0.8–12.0) 12.2 (5.6–23.2)
Certolizumab pegol 3 (948) 7 (962)
3.2 (0.7–9.3) 7.3 (2.9–15.0)
Golimumab 0 (1104) 5 (1119)
0.0 (0.0–2.7) 4.5 (1.5–10.4)
Tocilizumab 1 (1008) 5 (1030)
1.0 (0.0-5.5) 4.9 (1.6–11.3)
Rituximab 4 (851) 8 (830)
4.7 (1.3–12.1) 9.6 (4.2–19.0)
Abatacept 2 (1775) 7 (1767)
1.1 (0.1–4.1) 4.0 (1.6–8.2)
ILD interstitial lung disease, PY person-year, CI confidence interval, TNFα tumor
necrosis factor alpha
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derived from administrative claims may not fully adjust
for these differences, and any bias resulting from incom-
plete adjustment for confounding will bias the results in
favor of anti-TNF therapies.
The proportion of patients with newly diagnosed ILD
in our study ranged from 0.1 % to 0.4 %, depending on
the ILD definition employed. Similarly, ILD incidence
rates per 1000 PY ranged from 1.8 to 6.4. The frequency
of ILD complications or exacerbation in patients with
pre-existing ILD occurred in 4.1 %–8.4 % of patients at
rates between 65.8 and 127.7 per 1000 PY. The inci-
dence rates observed in the present study are similar to
those previously reported, despite a markedly shorter
follow-up window. Suissa et al. reported an ILD inci-
dence rate of 0.81 per 1000 PY in their 2006 study asses-
sing the impact of leflunomide on ILD risk [22].
Herrinton et al., in their 2013 evaluation of methotrexate
and anti-TNFα agents, reported an age/sex-standardized
ILD incidence rate, per 1000 PY, of 2.1 (95 % CI 0.0–4.3),
with incident ILD observed in 0.8 % of patients with RA
treated with an anti-TNF agent and 0.7 % in the metho-
trexate step-up cohort [19]. Dixon et al. [14] observed in-
cident ILD in 2.8 % of patients receiving anti-TNFα
agents, whereas Koike et al. [23] and Takeuchi et al. [24]
reported rates of 0.6 % and 0.5 %, respectively.
The present study found that older patients, men, and
patients with a history of other pulmonary disorders or
recent exposure to glucocorticoids were at increased risk
for developing ILD. Exposure to T-cell, B-cell, and IL-6
inhibitors was not significantly associated with increased
ILD risk compared with exposure to an anti-TNFα
agent. These data are largely consistent with those of the
existing literature. Herrinton et al., in a cohort of pa-
tients with autoimmune disease, including RA, found
that the risk of ILD was not increased in patients with
exposure to anti-TNF therapy versus exposure to non-
biologic disease-modifying anti-rheumatic drugs. Wolfe
et al. estimated ILD risk by using inpatient and death
record data, concluding that the only current treatment
associated with hospital-associated ILD was glucocorti-
coids, although past exposure to a number of biologic
agents (e.g., infliximab and etanercept) was associated
with increased risk of ILD hospitalization [25]. Bongartz
et al., using data from medical records, matched a co-
hort of patients with RA to those without the disease
and found that the risk of developing ILD was higher in
RA patients who were older at the time of disease onset,
in male patients, and in individuals with more severe
RA. The authors did not include biologic exposure in
the analysis, but multivariate results did find that a his-
tory of methotrexate or glucocorticoids was associated
with increased risk [26]. Chen et al. used high-resolution
CT and pulmonary function tests (PFTs) to identify
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represent precursors to more severe fibrotic lung disease
and concluded that patients with RA-ILD were older
and had longer disease duration, higher articular disease
activity, and more significant PFT abnormalities [27].
Several other studies have also found increased ILD risk
associated with older age, male gender, and high levels
of disease activity [23, 28–31].
ILD period prevalence in the present study was 4.2 %,
which is within the range of previously published esti-
mates. In a recent review of RA-associated ILD, O’Dwyer
et al. described the evolution of ILD prevalence estimates
beginning with Stack’s 1965 study based on chest radio-
graphs (5 %), Frank’s 1973 study based on diffusion cap-
acity (41 %), and Suzuki’s 1994 autopsy-based study (33 %)
and concluding with the Bongartz [27] study that esti-
mated 10-, 20-, and 30-year cumulative ILD incidence
based on clinical data, PFT results, radiological studies,
and lung biopsies [26]. The ranges reported by Bongartz
et al. (3.5 %–7.7 %) are similar to those of Turesson et al.,
who conducted a similar study and reported a 30-year
cumulative incidence for pulmonary fibrosis of 6.8 %
[26, 32]. In addition, Olson et al. reported the
prevalence of clinically significant ILD, defined as the
presence of ILD in RA-associated deaths, to be approxi-
mately 6.8 % in women and 9.8 % in men [31]. The life-
time risk of developing ILD in patients with RA is now
thought to be approximately 10 % [26].
Complications or exacerbation of ILD can be difficult
to determine in administrative data. The present study
used hospitalization for ILD, pneumonia, or lung trans-
plant as a proxy for ILD exacerbation, observing that these
complications occurred infrequently (4.1 %–8.4 %).
Among patients with existing ILD, being male and having
had a recent hospitalization for asthma, ILD, or pneumo-
nia in the 12 months prior to index were associated with
increased risk of an ILD-related hospitalization, whereas
exposure to methotrexate in the 6 months prior to index
was associated with significant reduction in an ILD-
related hospitalization. Although methotrexate may in fact
have a protective effect with respect to ILD exacerbation,
these results are perhaps more likely to reflect channeling
of patients with aggressive or severe ILD away from
methotrexate because these patients have less pulmonary
reserve were they to develop methotrexate-associated
pneumonitis.
Although several studies have examined mortality in
RA patients with ILD [14, 31, 33], we were able to iden-
tify only one study that reported the overall incidence
of ILD exacerbation and its risk factors. Hozumi et al.,
in a 2013 study in Japan, reported the overall 1-year in-
cidence of acute exacerbation of ILD in patients with
RA at 2.8 % [8]. The authors further concluded that
older age at ILD diagnosis, the usual interstitial pneu-
monia pattern on high-resolution CT, and methotrex-
ate usage were associated with the development of
acute exacerbation.
In an interpretation of our findings, several factors
should be considered. Although the present study was
based on a comparatively large and diverse sample of
patients with RA, it was not a random population
sample. The MarketScan databases are composed pri-
marily of employer-sponsored coverage for active em-
ployees, dependents, and retirees. The prevalence of
ILD or its complications might differ among those
covered by other payers or the uninsured. Moreover,
limited clinical information is available in these data-
bases other than the diagnostic information recorded
to support the claims for reimbursement. Patients
with ILD were identified according to ICD-9-CM
codes and were not confirmed by review of lung bi-
opsy or CT results. In addition, whereas considerable
literature details differences in ILD definition and de-
tection, few studies have attempted to validate an al-
gorithm for robust detection of this disease [19].
Since patients likely cycle between anti-TNFs before
being given the therapeutic option of an alternate
Table 4 ILD-related hospitalization rate per 1000 PY, unadjusted
Cohort Specific definition Sensitive definition
Events (total PY) Events (total PY)
Rate (95 % CI) Rate (95 % CI)
All eligible 4 (61) 42 (329)
65.8 (17.9–68.4) 127.7 (92.0–172.6)
Anti-TNFα agents 1 (28) 17 (152)
35.2 (0.9–195.9) 111.9 (65.2–179.1)
Etanercept 1 6 (33)
261.5 (6.6–1456.7) 180.6 (66.3–393.1)
Adalimumab 0 3 (45)
0.0 (0.0–253.9) 67.4 (13.9–197.0)
Infliximab 0 4 (15)
0.0 (0.0–1445.4) 262.5 (71.5–672.2)
Certolizumab 0 2 (28)
0.0 (0.0–761.4) 72.2 (8.7–260.7)
Golimumab 0 2 (31)
0.0 (0.0–439.8) 63.9 (7.7–230.8)
Tocilizumab 1 2 (36)
128.7 (3.3–717.1) 55.6 (6.7–200.7)
Rituximab 1 (13) 16 (68)
78.8 (95 % CI 2.0–439.1) 234.2 (95 % CI 133.8–380.3)
Abatacept 1 7 (73)
83.8 (95 % CI 2.1–467.0) 96.5 (95 % CI 38.8–198.7)
ILD interstitial lung disease, PY person-year, CI confidence interval, TNFα tumor
necrosis factor alpha
Curtis et al. Arthritis Research & Therapy  (2015) 17:319 Page 10 of 13
MOA, patients exposed to tocilizumab, rituximab, or
abatacept may have greater disease severity and dur-
ation. Because options for adjusting for RA disease se-
verity are limited in administrative claims, we selected
a population of patients who had previously discontin-
ued a different biologic agent prior to initiating the
agents evaluated in this study. The incidence of ILD in
individual exposure cohorts may still be confounded if
patients with higher levels of disease severity were
channeled to specific therapies. For example, prior
biologic exposure and corticosteroid use was highest
in patients in the tocilizumab and rituximab cohorts.
Hospitalizations for asthma, COPD, ILD, and pneumo-
nia were highest among patients with existing ILD
subsequently initiating rituximab. To the extent that
this is indicative of treatment resistance or disease se-
verity, ILD incidence and exacerbation in the toci-
lizumab and rituximab cohorts may be overstated. In
addition, given reports of rapid progression and in-
creased mortality amongst users of anti-TNFα agents
with existing ILD, it is also possible that clinicians are
channeling patients away from anti-TNF therapy and
toward other non-TNF biologics [14]. If such channel-
ing exists, we expect the risk estimates for the non-
TNF biologics to be greater than those observed with
anti-TNFα agents.
Conversely, the observed ILD incidence rate in our
study may have been suppressed by the limited length
of the study follow-up window, although it should be
noted that Roubille and Haraoui, in their systemic re-
view of the literature, noted that ILD occurs mostly
within the first 20 weeks after treatment initiation [18].
Similarly, Hadjinicolaou et al. summarized case reports
in a review of the clinical trial literature and reported
ILD cases occurring after relatively short exposures
[15]. Finally, the numbers of events in both primary
and secondary outcomes were small and, as such, may
have constrained the identification of statistical
significance.
Conclusions
Baseline differences exist between RA patients receiv-
ing anti-TNFα agents and agents with alternate MOAs.
Among patients with a history of biologic use, there
were no significant differences in the risk of ILD and
its related complications between RA patients receiving
anti-TNFα agents and RA patients receiving T-cell, B-
cell, and IL-6 inhibitors. Further studies are needed
that account for clinical and baseline differences in
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